{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:04:48Z","timestamp":1766138688401,"version":"3.40.5"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.humpath.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T15:12:32Z","timestamp":1715440352000},"page":"51-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas"],"prefix":"10.1016","volume":"148","author":[{"given":"Janira M.","family":"Navarro Sanchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian S.","family":"Finkelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Tyburski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley M.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Moisini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Katerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharlin","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M.","family":"Schiffhauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4208-7680","authenticated-orcid":false,"given":"Huina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.humpath.2024.05.002_bib1","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2217\/fon.14.19","article-title":"HER2 in solid tumors: more than 10 years under the microscope; where are we now?","volume":"10","author":"Martin","year":"2014","journal-title":"Future Oncol"},{"issue":"15","key":"10.1016\/j.humpath.2024.05.002_bib2","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2024.05.002_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early-stage uterine serous carcinoma: a multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2024.05.002_bib4","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.humpath.2024.05.002_bib5","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin\u2013paclitaxel compared with carboplatin\u2013paclitaxel\u2013trastuzumab in advanced (stage III\u2013IV) or recurrent uterine serous carcinomas that overexpress her2\/neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"volume":"vol. 2","year":"2018","key":"10.1016\/j.humpath.2024.05.002_bib6"},{"issue":"3","key":"10.1016\/j.humpath.2024.05.002_bib7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ygyno.2020.12.021","article-title":"Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations","volume":"160","author":"Hamilton","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"31","key":"10.1016\/j.humpath.2024.05.002_bib8","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.05.002_bib9","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/College of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.humpath.2024.05.002_bib10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American pathologists, American society for clinical pathology, and American society of clinical oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"10.1016\/j.humpath.2024.05.002_bib11","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.5858\/arpa.2022-0229-CP","article-title":"Current laboratory testing practices for assessment of ERBB2\/HER2 in endometrial serous carcinoma and colorectal carcinoma","volume":"147","author":"Hagemann","year":"2023","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"10.1016\/j.humpath.2024.05.002_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/ajcp\/aqad056","article-title":"HER2 in uterine serous carcinoma: current state and clinical perspectives","volume":"160","author":"Navarro Sanchez","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2024.05.002_bib13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 testing in endometrial serous carcinoma time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.humpath.2024.05.002_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2024.05.002_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.semdp.2021.10.006","article-title":"Immunohistochemistry in gynecologic carcinomas: practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors","volume":"39","author":"Buza","year":"2022","journal-title":"Semin Diagn Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2024.05.002_bib17","article-title":"Characteristics of HER2 gene amplification by fluorescence in situ hybridization in endometrial serous carcinoma","volume":"146","author":"Buza","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.humpath.2024.05.002_bib18","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/PAS.0000000000001682","article-title":"HER-2 amplification in uterine serous carcinoma and serous endometrial intraepithelial carcinoma","volume":"45","author":"Banet","year":"2021","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2024.05.002_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"year":"2011","series-title":"Statistical methods in diagnostic medicine. Wiley series in probability and statistics","author":"Zhou","key":"10.1016\/j.humpath.2024.05.002_bib20"},{"issue":"3","key":"10.1016\/j.humpath.2024.05.002_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1191\/1740774506cn147oa","article-title":"Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs","volume":"3","author":"Moskowitz","year":"2006","journal-title":"Clin Trials"},{"issue":"5","key":"10.1016\/j.humpath.2024.05.002_bib22","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1309\/AJCPT41TCBUEVDQC","article-title":"Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens: table 1","volume":"144","author":"Furrer","year":"2015","journal-title":"Am J Clin Pathol"},{"journal-title":"Immunohistochemistry Tissue Microarray HER2-A","article-title":"Surveys and anatomic pathology education programs","year":"2020","key":"10.1016\/j.humpath.2024.05.002_bib23"},{"journal-title":"Immunohistochemistry Tissue Microarray HER2-A","article-title":"Surveys and anatomic pathology education programs","year":"2023","key":"10.1016\/j.humpath.2024.05.002_bib24"},{"issue":"2","key":"10.1016\/j.humpath.2024.05.002_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ctrv.2013.09.001","article-title":"HER2 testing: current status and future directions","volume":"40","author":"Perez","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.humpath.2024.05.002_bib26","unstructured":"Hicks D, Lester S. Diagnostic Pathology Breast. 3rd edition. Elsevier."},{"issue":"3","key":"10.1016\/j.humpath.2024.05.002_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.prp.2015.11.016","article-title":"Interobserver reproducibility for HER2\/neu immunohistochemistry: a comparison of reproducibility for the HercepTestTM and the 4B5 antibody clone","volume":"212","author":"Layfield","year":"2016","journal-title":"Pathol Res Pract"},{"issue":"11","key":"10.1016\/j.humpath.2024.05.002_bib28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/modpathol.3880440","article-title":"HER-2\/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization","volume":"14","author":"Thomson","year":"2001","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2024.05.002_bib29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ajcp\/aqac184","article-title":"Interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low\u2013expressing breast cancer cohort","volume":"159","author":"Karakas","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2024.05.002_bib30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/PAI.0000000000000646","article-title":"Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with fluorescent in situ hybridization in breast carcinoma","volume":"27","author":"Lucas","year":"2019","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"10.1016\/j.humpath.2024.05.002_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00428-022-03378-5","article-title":"Comparison of HercepTestTM mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2\/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status","volume":"481","author":"R\u00fcschoff","year":"2022","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2024.05.002_bib32","article-title":"Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2\/neu (4B5) [abstract presented at the American Society of Clinical Oncology annual meeting 2021]","volume":"99","author":"Scott","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.humpath.2024.05.002_bib33","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/his.13704","article-title":"HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in\u2010situ hybridization","volume":"73","author":"Koopman","year":"2018","journal-title":"Histopathology"},{"issue":"12","key":"10.1016\/j.humpath.2024.05.002_bib34","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2024.05.002_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2024.05.002_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/PGP.0000000000000943","article-title":"HER2 status assessment in endometrial serous carcinoma: comparative analysis of two proposed testing and interpretation algorithms","volume":"43","author":"Hashem","year":"2024","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2024.05.002_bib37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/10668969221102529","article-title":"The prognostic effect of HER2 gene amplification in high-grade endometrial carcinomas and its correlation with protein overexpression","volume":"31","author":"Bozkurt","year":"2023","journal-title":"Int J Surg Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2024.05.002_bib38","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.clbc.2021.05.004","article-title":"Discordance between immunohistochemistry and in situ hybridization to detect HER2 overexpression\/gene amplification in breast cancer in the modern age: a single institution experience and pooled literature review study","volume":"22","author":"Memon","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.humpath.2024.05.002_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/PAI.0b013e31804c7283","article-title":"Recommendations for improved standardization of immunohistochemistry","volume":"15","author":"Goldstein","year":"2007","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"11","key":"10.1016\/j.humpath.2024.05.002_bib40","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/modpathol.2009.117","article-title":"Delay to formalin fixation effect on breast biomarkers","volume":"22","author":"Khoury","year":"2009","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2024.05.002_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/modpathol.2012.123","article-title":"Delay to formalin fixation \u2018cold ischemia time\u2019\u2019: effect on ERBB2 detection by in-situ hybridization and immunohistochemistry","volume":"26","author":"Portier","year":"2013","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.humpath.2024.05.002_bib42","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/modpathol.2012.59","article-title":"The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma","volume":"25","author":"Yildiz-Aktas","year":"2012","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.humpath.2024.05.002_bib43","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1038\/bjc.2014.147","article-title":"Impact of HER2 copy number in IHC2+\/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network","volume":"110","author":"Borley","year":"2014","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.humpath.2024.05.002_bib44","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6605939","article-title":"Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer","volume":"103","author":"Guiu","year":"2010","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2024.05.002_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.humpath.2024.05.002_bib46","first-page":"155","article-title":"HER-2\/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma","volume":"57","author":"Horiguchi","year":"2010","journal-title":"J Med Dent Sci"},{"issue":"1","key":"10.1016\/j.humpath.2024.05.002_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724000868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724000868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T19:35:51Z","timestamp":1716406551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817724000868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":46,"alternative-id":["S0046817724000868"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2024.05.002","relation":{},"ISSN":["0046-8177"],"issn-type":[{"type":"print","value":"0046-8177"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}